Stemline Therapeutics Inc. (NASDAQ:STML) saw unusually-high trading volume on Tuesday . Approximately 146,407 shares were traded during trading, an increase of 52% from the previous session’s volume of 96,200 shares.The stock last traded at $7.33 and had previously closed at $7.17.

STML has been the subject of a number of analyst reports. Jefferies Group reiterated a “buy” rating and set a $23.00 target price on shares of Stemline Therapeutics in a report on Monday, June 6th. Roth Capital reiterated a “buy” rating and set a $32.00 target price on shares of Stemline Therapeutics in a report on Tuesday, May 10th. Zacks Investment Research upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a report on Wednesday, July 6th. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 target price on shares of Stemline Therapeutics in a report on Tuesday, June 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Stemline Therapeutics has a consensus rating of “Buy” and a consensus target price of $19.56.

The company’s market capitalization is $130.15 million. The company has a 50 day moving average of $7.37 and a 200 day moving average of $5.73.

Stemline Therapeutics (NASDAQ:STML) last announced its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.08. The company earned $205.65 million during the quarter, compared to analysts’ expectations of $121.43 million. Equities research analysts anticipate that Stemline Therapeutics Inc. will post ($2.23) EPS for the current fiscal year.

A hedge fund recently raised its stake in Stemline Therapeutics stock. Royce & Associates LLC raised its position in Stemline Therapeutics Inc. (NASDAQ:STML) by 318.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 159,179 shares of the biopharmaceutical company’s stock after buying an additional 121,179 shares during the period. Royce & Associates LLC owned about 0.91% of Stemline Therapeutics worth $1,004,000 as of its most recent filing with the SEC.

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.